Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASHSOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE ...

EFX is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 4.4% year-over-year for the current fiscal year, with sales growth of 5.7%.

Efx Fragments is available now at an introductory price of $99, though if you already own other Arturia products there's probably a steep discount waiting for you.

Exodus to Jazz is bringing contemporary jazz guitarist, composer, and arranger Chieli Minucci with his Grammy-nominated jazz-fusion group Special EFX to the Lutheran Church of the Reformation on ...

Aaron Schurman fell in love with casino gaming at a young age and decided to bring the concept home. His company, Phantom EFX, became known for creating casino games for home entertainment, especially ...